Skip to main content
Equibles
MAIA logo

MAIA · MAIA Biotechnology, Inc. · Investor Relations

Track MAIA — free

Use MAIA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MAIA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.01 +0.00 (+0.00%)
Rebalance outlook locked
Market Cap
$62.37M
Shares
61.75M
Volume · Nov 12 273.94K Avg daily vol (3M) 447.24K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-04-16 MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer
2026-04-08 MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
2026-03-31 MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
2026-03-04 MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
2026-03-04 MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
2026-03-04 MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
2026-02-24 MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
2026-01-20 MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
2025-12-17 MAIA Biotechnology Announces $1.51 Million Private Placement
2025-12-11 MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
2025-12-11 MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
2025-12-11 MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential
2025-12-10 MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
2025-11-21 MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
2025-11-20 MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation

Past events

Date Event Type
2026-05-21 Annual Meeting of Shareholders Shareholder meeting

Source: https://ir.maiabiotech.com/

Key facts CIK 1878313 CUSIP 552641102 13F (30d) 17 filings 17 filers Visit website Investor relations